CN112142827B - gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof - Google Patents
gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof Download PDFInfo
- Publication number
- CN112142827B CN112142827B CN201910577700.XA CN201910577700A CN112142827B CN 112142827 B CN112142827 B CN 112142827B CN 201910577700 A CN201910577700 A CN 201910577700A CN 112142827 B CN112142827 B CN 112142827B
- Authority
- CN
- China
- Prior art keywords
- protein
- subunit
- pseudorabies virus
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 title claims abstract description 50
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 96
- 239000013612 plasmid Substances 0.000 claims abstract description 17
- 101150029683 gB gene Proteins 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 6
- 238000010367 cloning Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 88
- 229960005486 vaccine Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 208000009305 pseudorabies Diseases 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 25
- 239000000523 sample Substances 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 19
- 238000001179 sorption measurement Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000007788 liquid Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 229940031626 subunit vaccine Drugs 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 238000001976 enzyme digestion Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 101150003230 UL27 gene Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 pH 9.5) Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000012879 subculture medium Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides gB subunit recombinant protein of porcine pseudorabies virus, a preparation method and application thereof, wherein the preparation method comprises the steps of 1) cloning an optimized gB gene sequence into a eukaryotic expression vector to obtain a recombinant plasmid containing a gB subunit protein coding gene of the pseudorabies virus; 2) Then the recombinant plasmid containing the gB subunit protein coding gene of the pseudorabies virus is transfected into an expression cell; 3) Culturing, screening and domesticating the expression cells in the step 2) to obtain a highly expressed cell strain; 4) Fermenting and culturing the cell strain in the step 3), and purifying to obtain the gB subunit protein of the pseudorabies virus. The invention can provide the porcine pseudorabies virus gB subunit protein which can be industrially produced in a large scale, and has the advantages of simple preparation method, low cost and far higher yield than the prior baculovirus expression system.
Description
Technical Field
The invention belongs to the field of gene recombination expression in biotechnology. Relates to gB subunit recombinant protein of porcine pseudorabies virus, a preparation method and application thereof.
Background
The porcine Pseudorabies is an acute infectious disease which is caused by porcine Pseudorabies virus (PrV) and causes abortion of sows, central nervous system disorder of newborn piglets and respiratory symptoms and death of weaned piglets, and brings huge economic loss to the pig industry. At present, the main measure for preventing and controlling the disease is vaccination. The subunit vaccine does not contain nucleic acid, the generated immune response can be distinguished from the wild strains, continuous infection or latent infection can not be caused after inoculation, and the safety is better. However. Currently, subunit vaccines are limited in their use due to the high cost of protein production.
PRV belongs to the family of herpesviridae, and the virus is spherical, with a capsule and fiber processes. The virus surface has identified 11 glycoproteins: gB (gII), gC (gIII), gD (gp 50), gE, gG, gH, gI, gK, gL, gM, and gN. Wherein gB glycoprotein is encoded by UL27, also called gII glycoprotein, and consists of three proteins of gIIa, gIIb and gIIc, wherein gIIb and gIIc are obtained by hydrolysis of gIIa. The gB protein is found to be an important neutralizing protein of pseudorabies virus, and can promote the fusion of the cell outer membrane and the virus envelope. Therefore, the gB protein is a good protective antigen, and the subunit vaccine prepared by the gB protein can resist the attack of the strong virus of the pseudorabies virus.
gB is a glycosylated protein in order to better maintain its structural stability and immunogenicity. It is desirable to express the protein using eukaryotic systems. Patent CN 105693827A is a porcine pseudorabies virus subunit vaccine and a preparation method and application thereof. The method successfully expresses the pseudorabies virus gB protein by utilizing a baculovirus system, and provides a method for producing a gB subunit vaccine. However, the yield was only 6mg/L. For veterinary vaccine applications, the yield is still relatively low. In addition, the glycosylated protein modification expressed by baculovirus of insect cells generally has only high-mannose type sugar chains or oligomannose sugar chains, and the end of the sugar chains has few residues such as galactose, sialic acid and the like, which is different from the glycosylation modification mode and degree of higher organisms. Only when expressed in mammalian cells, the glycoprotein has structural and physiological biochemical characteristics closer to those of the natural state. Therefore, the development of a production method of gB protein which has low production cost, high production yield and a protein structure closer to the natural protein has important practical significance for application of pseudorabies subunit vaccines, development of diagnostic kits and the like.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a recombinant gB subunit protein on the surface of porcine pseudorabies virus, which can be industrially produced in a large scale.
In order to solve the problem, on the one hand, the inventor obtains a gB subunit recombinant protein of porcine pseudorabies virus with stable structure by completely analyzing and researching the currently available information of porcine pseudorabies virus and removing the transmembrane region and the intracellular region without protective antigen in the gB protein through structural analysis of the overall structure of the gB protein, wherein the gB subunit recombinant protein is the extracellular region of the gB protein, and the amino acid sequence of the gB subunit recombinant protein is shown as SEQ ID No. 3.
According to the technical scheme of the invention, preferably, the gene sequence coded by the gB subunit recombinant protein is shown as SEQ ID NO. 2.
According to the technical scheme of the invention, preferably, the gene sequence coded by the gB subunit recombinant protein can efficiently secrete and express an optimized gB gene sequence of the gB subunit protein in a CHO cell, and the optimized gB gene sequence is shown in SEQ ID NO. 1.
According to the technical scheme of the invention, preferably, the gB subunit recombinant protein can be connected with a detection or purification tag at the amino terminal or the carboxyl terminal of the amino acid sequence shown as SEQ ID NO.3, wherein the tag is one selected from ploy-Arg, ploy-His, FLAG, c-myc and HA. Here, in order to make the subunit gB protein convenient for detection or purification, one skilled in the art can attach a tag as shown in table one to the amino terminus or carboxy terminus of the amino acid sequence shown in SEQ ID No.3, specifically exemplified by Poly-His in this example, to the carboxy terminus of the amino acid sequence shown in SEQ ID No.3 by conventional technical means.
TABLE-TAGS AND AMINO ACID SEQUENCES THEREOF
According to the technical scheme of the invention, preferably, the porcine pseudorabies virus subunit protein comprises a derived protein which is obtained by substituting, deleting or adding one amino acid or a plurality of amino acids in an amino acid sequence shown as SEQ ID NO3 and has immunogenicity.
According to the technical scheme of the invention, preferably, the amino acid of the porcine pseudorabies virus gB is from a strain comprising porcine pseudorabies virus bartha, heN1, NVDC-PRV-BJ, PRV-TJ, fa and Becker; porcine pseudorabies virus variant strains PRV-ZJ01, HN1201, HN1202 and the like. The porcine pseudorabies virus gB subunit protein is the glycoprotein of the herpes virus members that is most conserved.
According to the technical scheme of the invention, preferably, the expression system of the porcine pseudorabies virus subunit gB protein is a mammalian cell.
According to the technical solution of the present invention, preferably, the mammalian cell is a CHO cell.
According to another aspect of the present invention, there is provided a method for preparing porcine pseudorabies virus gB protein, comprising: 1) Cloning the optimized gB gene sequence shown as SEQ ID NO.1 into a eukaryotic expression vector to obtain a recombinant plasmid containing a gB subunit protein coding gene of the pseudorabies virus; 2) Then the recombinant plasmid containing the gB subunit protein coding gene of the pseudorabies virus is transfected into an expression cell; 3) Culturing, screening and domesticating the expression cells in the step 2) to obtain a highly expressed cell strain; 4) And (4) fermenting and culturing the cell strain in the step 3), and purifying to obtain gB subunit protein of the pseudorabies virus, wherein the amino acid sequence of the gB subunit protein is shown as SEQ ID NO. 3.
In the technical solution of the present invention, preferably, in step 1), the eukaryotic expression vector may be pee6.4, pee12.4, pgl4.13, pcdna3.1; preferably, the eukaryotic expression vector is pEE12.4 or pcDNA3.1.
In the technical solution of the present invention, preferably, in step 2), the expression cell is a mammalian cell.
In the technical solution of the present invention, preferably, the mammalian cell is a CHO cell or 293T cell.
In the technical solution of the present invention, preferably, the CHO cell includes DG44, DXB11, CHO-K1, CHO-S cell line, preferably, the CHO cell is CHO-K1 cell.
According to still another aspect of the present invention, the present invention provides a use of a gB subunit recombinant protein of porcine pseudorabies virus in the preparation of a vaccine for diagnosing, preventing and treating porcine pseudorabies.
The invention constructs and screens the suspension stable high-efficiency CHO cell strain secreting and expressing the pseudorabies virus gB protein, the cell strain expresses the pseudorabies virus gB protein with high yield (the yield is up to 0.8-1.2 g/L), is far higher than the prior expression technology, is easy to purify (as shown in figure 4, the purity of the target protein can reach more than 90 percent only by one-step affinity chromatography, and the invention far meets the requirements of subunit vaccines and diagnostic reagents), and is easy for large-scale production. Therefore, the problem of high production cost of the protein, which is a defect of the gB subunit vaccine of the pseudorabies virus, is solved. In addition, the CHO cell strain for production has high controllability during culture, easy quality control, stable production protein batch-to-batch, and high biosafety (no virus, no risk of virus dispersion).
Drawings
FIG. 1 shows the alignment results before and after optimization of the gB gene sequence.
FIG. 2 shows a map of the pEE12.4-OPTI-gB plasmid.
FIG. 3 shows the results of the double-restriction enzyme identification of pEE12.4-OPTI-gB: m is a DNA Marker: DL10000Marker;1 is the result of pEE12.4-OPTI-gB double-enzyme digestion electrophoresis, and the enzyme digestion sizes are 8746bp and 2172bp respectively.
FIG. 4 shows SDS-PAGE purification assay of recombinant gB: 1 is a protein Marker, and 2 is a purified glycosylated gB protein with the molecular weight of about 130Kd (the loading buffer does not contain reducing agents such as beta-mercaptoethanol and the like).
FIG. 5 shows the West-blot assay of recombinant gB proteins: 1 is maker,2 is purified gB protein, and the western results show that the band is approximately 130Kd, which is consistent with the size of SDS-PAGE.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and examples, which are only for illustrating the technical solutions of the present invention and are not to be construed as limiting the present invention.
The strains, plasmids and reagents used in the examples of the present invention are all commercially available products.
The sources of the reagent and the medicine of the invention are listed as follows:
the CHO-K1 cells are derived from cell banks of China academy of sciences type culture Collection cell banks, shanghai Life sciences research institute of China academy of sciences;
cell culture medium and serum were purchased from gibco, usa;
the eukaryotic expression vector pEE12.4 is purchased from Shanghai Linyuan Biotech, inc.;
lipofectamine LTX was purchased from Thermo Fisher, USA;
methionine sulfoxide ammonium sulfite (MSX) was purchased from Sigma;
BCA protein quantification kit was purchased from Thermo Fisher, USA.
Example 1gB protein expression and preparation
1.1 selection of porcine pseudorabies gB protein
The porcine pseudorabies virus surface glycoprotein gB is a segment of polypeptide coded by UL27 gene, amino acids 1-800 are predicted to be the extracellular region of gB protein, a transmembrane region is arranged at amino acids 801-821, and amino acids 822-916 are the intracellular regions. The extracellular domain of the gB protein has stable structure and good immunogenicity, and is the main antigen for producing gB subunit vaccines. At present, the protein can be expressed and purified in a large scale in a mammalian system, which is an important technical problem to be solved by the invention.
1.2 codon optimization of gB protein of porcine pseudorabies virus
The gB protein is the most conserved protein on the surface of the porcine pseudorabies virus, the homology is high, the classical strain Bartha strain (GenBank: JF 797217.1) is taken as a template in the laboratory, the gB gene is optimally synthesized, the gB expression vector is constructed, and the gB protein is expressed and purified. Therefore, gB proteins from other strains can also be prepared by this method. Combining the experience of the previous research on the envelope protein of the expressed virus, through the research on the protein structure prediction and the structure of the amino acid, the partial sequence of the N-terminal extracellular region and the C-terminal transmembrane region and intracellular region which are not beneficial to recombinant expression are removed, and the extracellular region with stable structure of the porcine pseudorabies virus protein is selected as the immunogenic protein, namely the amino acid of 41V-754N. Since the amino acids encoded by the start codon of eukaryotes are all methionine (M), we add one methionine (M) before 41V in designing expression, i.e., designing the amino acid sequence of the recombinant expression gB protein 40M-754N. In order to facilitate the better stable and efficient expression of the porcine pseudorabies virus gB gene in a CHO system, the nucleotide sequence for coding the gB protein is subjected to codon optimization as shown in SEQ ID NO.2 to obtain an OPTI-gB sequence as shown in SEQ ID NO.1, and the sequence synthesis work is entrusted to Nanjing Kinsry Biotechnology Co., ltd. As shown in FIG. 2, the nucleotide sequences differed by 19.3% before and after the optimization.
Example 2: construction of pEE12.4-OPTI-gB recombinant plasmid
2.1PCR amplification of the fragment of interest OPTI-gB
2.1.1PCR reaction
(1) Primer design and Synthesis
Upstream primer of 5' cgaagCTTGCCGCCACCATGGCTC-3
Downstream primer of 5' cgAATTCTCAATGGTGATGGGTGATGGTGATTATGATCCACCTT-3
(2) Sample loading system 50 μ L, as shown in the following table:
PCR amplification procedure:
2.1.2PCR products for gel recovery
(1) Marking a sample collection EP tube, an adsorption column and a collection tube;
(2) Weighing the weight of the marked empty EP pipe, and recording the numerical value;
(3) A single DNA band of interest was carefully excised from the agarose gel on a gel cutter with a scalpel and placed into a clean 1.5mL centrifuge tube;
(4) Adding 600 mu L of PC buffer into the 1.5mL centrifuge tube in the step (3), placing in a water bath at 50 ℃ for about 5min, and turning the centrifuge tube up and down continuously and gently to ensure that the gel block is fully dissolved;
(5) Column balancing: adding 500 μ L of balance liquid BL into adsorption column CB2 (the adsorption column is placed into the collection tube in advance), centrifuging at 12,000rpm/min for 1min, pouring off waste liquid in the collection tube, and placing the adsorption column back into the collection tube;
(6) Adding the solution obtained in the step (5) into an adsorption column CB2, standing for 2min, standing for 10,000rpm/min, centrifuging for 30s, pouring out waste liquid in a collecting pipe, and then putting the adsorption column CB2 into the collecting pipe;
(7) Adding 600 mu L of rinsing liquid PW buffer into the adsorption column, standing for 3min, centrifuging at 10,000rpm/min for 30s, pouring out waste liquid in the collecting pipe, and putting the adsorption column CB2 into the collecting pipe;
(8) Repeating the step (7);
(9) Centrifuging with air adsorption column at 12,000rpm/min for 2min, removing rinsing liquid as much as possible, standing the adsorption column at room temperature for 10min, and air drying completely;
(10) Placing adsorption column CB2 into a collecting pipe, suspending and dropwise adding 50 μ L of precipitation buffer (preheated at 65 ℃) to the middle position of an adsorption film, standing for 3min, centrifuging for 12,000rpm/min, and centrifuging for 2min;
(11) Taking out the centrifuge tube in the step (10) from the centrifuge, discarding the middle adsorption column CB2, covering the centrifuge tube with a cover, and keeping the DNA sample in the centrifuge tube;
(12) And (3) storing the DNA sample in the step 11 at 4 ℃, and preparing an agarose gel electrophoresis identification gel to recover the DNA fragment.
2.2 double digestion of PCR products and vectors
(1) The 1.5mL EP tubes needed were labeled and loaded and mixed in the 1.5mL EP tubes according to the following table: 50 μ L reaction System
(2) And (3) placing the 1.5mL EP tube in the step (1) into a corresponding enzyme constant-temperature water bath kettle with the optimal temperature, and carrying out water bath for 2-3h.
Recovering the double enzyme digestion product glue: taking out the double enzyme digestion system, and carrying out agarose gel electrophoresis to recover the DNA fragment in the double enzyme digestion system, wherein the method is the same as that for recovering the PCR product gel in 1.2.1.
2.3 ligation reaction
(1) A plurality of clean 1.5mL EP tubes are prepared, marked and placed on an EP tube frame for standby.
(2) The sample was loaded and mixed in a 1.5mL EP tube as described in the following table.
(3) After the sample is added according to the table in the step (2), putting each 10 mu l reaction system into a low-temperature cooling liquid circulator at the temperature of 16 ℃ for water bath for 10-16h;
(4) Taking out the EP tube in the step (3), placing the EP tube in a water bath kettle at 65 ℃, and carrying out water bath for 15min;
(5) Taking out the EP tube in the step (4), and storing at 4 ℃.
2.4 conversion reaction
(1) Quickly adding 10 μ L of the ligation reaction solution into 100 μ L of competent cells, uniformly mixing by blowing, and carrying out ice bath for 30min;
(2) Taking out the sample tube, placing in water bath at 42 ℃ for 100s, and immediately carrying out ice bath for 2min;
(3) Taking out the sample tube, adding 600 mu L of liquid LB culture medium into the sample tube in a super-clean workbench, then placing the sample tube in a constant temperature shaking table at 37 ℃, and culturing for 1h at 220 rpm/min;
(4) Coating a plate: and (4) taking out the sample tube in the step (3), centrifuging at room temperature for 8,000rpm/min for 2min, removing 600 mu L of supernatant liquid, re-suspending thalli at the bottom of the tube by the residual supernatant liquid, putting the re-suspended bacterial liquid into the center of a corresponding transformation plate, and uniformly spreading the bacterial liquid in the center of the transformation plate by using a bacteria coating rod.
(5) The flat plate in the transformation step (4) is placed in a biochemical constant-temperature incubator, and is cultured for 1h at 37 ℃, and then the transformation flat plate is inverted and cultured for 15h;
(6) The transformation results were observed.
2.5 plasmid extraction and double digestion identification
2.5.1 plasmid extraction
(1) Picking the monoclonal from the transformation plate by using a 10 mu L pipette tip into 5mL LB liquid culture medium containing benzyl amine resistance, shaking the bacteria at 37 ℃ and 220rpm/min overnight;
(2) Transferring the bacterial liquid into a 1.5mL EP tube, centrifuging at room temperature for 2min at 12,000rpm, and discarding the supernatant;
(3) Adding 250 mu L of plasmid extraction reagent P1buffer into the EP tube in the step (2) to completely suspend the thalli;
(4) Adding 250 mu L of P2buffer into the solution in the step (3), immediately and gently inverting the centrifuge tube for 5-10 times, uniformly mixing, and standing at room temperature for 2-4min;
(5) Adding 350 mu L of P3buffer into the solution in the step (4), immediately and gently reversing the centrifuge tube for 5-10 times, and uniformly mixing; standing at room temperature for 2-4min;
(6) Centrifuging the solution in the step (5) at room temperature for 10min at 14,000rpm;
(7) Transferring the supernatant solution in the step (6) to the center of an adsorption column, centrifuging at room temperature for 12,000rpm/min for 30s, and pouring out liquid in a collecting pipe;
(8) Adding 500 μ L Buffer DW1 into the center of the adsorption column, centrifuging at room temperature for 12,000rpm/min for 30s, and pouring out the liquid in the collection tube;
(9) Adding 500 mu L wash solution into the center of the adsorption column, centrifuging at room temperature for 12,000rpm/min for 30s, pouring out liquid in the collection tube, and repeating the steps once;
(10) Empty adsorption column, centrifuge at room temperature, 12,000rpm,2min.
(11) The adsorption column was placed in a clean 1.5mL centrifuge tube, 30. Mu.L of Elutionbuffer was added to the center of the adsorption membrane, allowed to stand at room temperature for 5min, centrifuged at room temperature, 12,000rpm,2min. The DNA solution in the tube was stored.
2.5.2 double restriction enzyme identification
(1) The 1.5mL EP tubes were labeled for use and loaded as follows: 20 μ L reaction System
(2) And (2) putting the EP tube 20 mu L of reaction system in the step (1) into a constant-temperature water bath kettle at 37 ℃ for water bath for 2h.
(3) Carrying out agarose gel electrophoresis on the double enzyme digestion system sample in the step (2), and checking whether the size of the inserted fragment is correct; the results of the experiment are shown in FIG. 2: the enzyme digestion identification construction is correct.
(4) Clones with correct inserts were selected for sequencing by the sequencing company. And (4) storing the plasmid with the correct sequencing result for later use.
Example 3: establishment of pEE12.4-OPTI-gB recombinant plasmid transfection CHO-K1 cell and monoclonal screening
3.1CHO-K1 cell transfection
(1) Preparing: sterilizing the biological safety cabinet for 30min by ultraviolet; DMEM/F12 (containing 10% serum and 1% double antibody), DMEM/F12 and PBS were preheated to 37 ℃ in a 37 ℃ water bath.
(2) The cells (10 cm cell culture dish) were removed from the 37 ℃ incubator, the supernatant medium was discarded, the cells were washed once with pre-warmed 8mL PBS, and the PBS was discarded.
(3) Adding 0.25% of trypsin-EDTA per 10cm cell culture dish, digesting at room temperature for about 2min, observing under microscope that the cells shrink and become round and present as single cells.
(4) The digestion reaction was stopped by adding 4mL of DMEM/F12 (10% serum, 1% double antibody) and the cells were pipetted off.
(5) The digested cells were transferred to a 15mL centrifuge tube and centrifuged at room temperature for 200g,5min.
(6) The cells were resuspended in DMEM/F12 (10% serum, 1% double antibody) and counted.
(7) Dilute cells to 2 × 10 5 cell/mL, 2mL of the mixed cells were added to a six-well plate, the six-well plate was set to 37 ℃,5% 2 Incubate overnight in a cell incubator.
(8) Taking out the cell culture dish in the step (7), and observing the cell state: transfection was initiated when cell confluence reached 80% -90%, and the medium was changed to antibiotic-free and serum-free DMEM/F12,2 mL/well before transfection.
(9) Plasmid dilution: the plasmid was diluted with OPTI-MEM, and 2.5. Mu.g of the plasmid was added to 125. Mu.L of OPTI-MEM, followed by 2.5. Mu.L of plus, followed by mixing, and the mixture was allowed to stand at room temperature for 5min.
(10) Dilution of Lipofectamine LTX: mu.L of OPTI-MEM was added with 9. Mu.L of Lipofectamine LTX, followed by 2.5. Mu.L of plus, gently mixed, and allowed to stand at room temperature for 5min.
(11) And (4) lightly mixing the mixture obtained in the step (10) and the step (11). Standing at room temperature for 5min, and then dropwise adding into a six-hole plate for uniform distribution.
(12) Placing the six well plates at 37 ℃ 5% CO 2 Culturing in a cell culture box for 4-6h.
(13) Liquid changing: the supernatant medium was discarded, 2mL of DMEM/F12 (containing 10% serum and 1% double antibody) was added, and the six-well plate was set at 37℃，5％CO 2 Culturing in a cell culture box.
3.2 pressure screening
Pressurization was started 24h after transfection: the six-well plate cells were removed from the 37 ℃ incubator, the supernatant medium was discarded, 2mL of DMEM/F12 (containing 10% serum + 25. Mu.M MSX) was added, the pressure was increased for 7days, the cells were observed in the middle, and the dead cells were changed.
3.3 monoclonal screening
(1) The monoclonal selection was initiated at approximately 7days when the negative control cells were essentially dead by pressure selection.
(2) The six well plate was removed, the medium was discarded, PBS was washed once, then 300. Mu.L of 0.25% trypsin-EDTA was added, the mixture was digested at room temperature for about 2min, 2mL of DMEM/F12 (containing 10% serum + 25. Mu.M MSX) was added to terminate the digestion reaction, and the cells were blown off by a pipette.
(3) The digested cells were transferred to a 15mL centrifuge tube and centrifuged at room temperature for 200g,5min.
(4) Cells were resuspended in DMEM/F12 (containing 10% serum + 25. Mu.M MSX) and counted.
(5) Plate paving: diluting the cells to 5/mL, adding 200. Mu.L of the mixed cells to a 96-well plate, standing to 37 ℃,5% 2 And incubating for 4-6h in the cell incubator.
(6) Wells of individual cells were recorded.
(7) When the wells of the individual cells in the 96-well plate were grown up, the medium was discarded, PBS was washed once, 100. Mu.L of 0.25% trypsin-EDTA was added, digestion was carried out at room temperature for about 2min, digestion was terminated by adding 2mL of DMEM/F12 (containing 10% serum + 25. Mu.M MSX), and the cells were blown off by a pipette. And transferring the cell sap to a 12-pore plate, taking the supernatant when the 12-pore plate is full, detecting whether the clone is positive by dot-blot, and continuously performing amplification culture and freezing storage on the high-efficiency expression positive clone.
Example 4: CHO-K1 cell strain domesticated into suspension culture
(1) Preparing: sterilizing the biological safety cabinet for 30min by ultraviolet; DMEM/F12 (containing 10% serum, 25. Mu.M MSX) was preheated to 37 ℃ in a 37 ℃ water bath.
(2) The cells (10 cm cell culture dish) were removed from the 37 ℃ incubator, the supernatant medium was discarded, the cells were washed once with pre-warmed 8mL PBS, and the PBS was discarded.
(3) Adding 0.25% of trypsin-EDTA per 10cm cell culture dish, digesting at room temperature for about 2min, observing under microscope that the cells shrink and become round and present as single cells.
(4) Digestion was stopped by adding 4mL of DMEM/F12 (containing 10% serum, 25. Mu.M MSX) and the cells were blown off with a pipette.
(5) The digested cells were transferred to a 15mL centrifuge tube and centrifuged at room temperature for 200g,5min.
(6) Cells were suspended in 100% DMEM/F12 (containing 10% serum, 25. Mu.M MSX) and counted.
(7) Dilute cells to 5 × 10 5 One cell/mL was inoculated into a 30mL culture medium in a 125mL shake flask. The cell culture flask was left at 37 ℃ and 5% CO 2 Incubate overnight on an orbital shaker in a cell incubator at 120 rpm/min.
(8) Wiping the biological safety cabinet table top with 75% alcohol for sterilization, and irradiating with ultraviolet for 30min.
(9) Cell density and viability were counted every 24 h.
(10) And performing second-generation culture when the cell survival rate reaches 94-97% after the first-generation cell culture is performed once.
(11) Preparing: sterilizing the biological safety cabinet for 30min by ultraviolet; 100% DMEM/F12 (containing 10% serum, 25. Mu.M MSX), EX-CELL 302 in CO 2 The cell incubator was preheated to 37 ℃.
(12) The cells were removed from the 37 ℃ incubator, transferred to a 50mL centrifuge tube, and centrifuged at 200g for 5min at room temperature.
(13) DMEM/F12 (containing 10% serum, 25. Mu.M MSX) and EX-CELL 302 were mixed as 1:1 mixing, resuspending the cells, and counting.
(14) Dilute cells to 5 × 10 5 cells/mL were inoculated in 30mL culture medium in a 125mL shake flask. Placing the cell culture flask at 37 deg.C, 5% 2 Incubate overnight on an orbital shaker in a cell incubator at 120 rpm/min.
(15) Wiping the biological safety cabinet table top with 75% alcohol for sterilization, and irradiating with ultraviolet for 30min.
(16) Cell density and viability were counted every 24 h.
(17) The survival rate of the cells obtained after the second-generation culture is more than 95 percent; the cell survival rate obtained after three times of culture of the third generation to the sixth generation is more than 95 percent. After 7 weeks, the cells were seeded for 3 days and propagated for three generations with a density of 1X 10 6 Individual cells/mL with a cell viability of 95%, which cells are considered to have been adapted to suspension culture. The inoculation density is reduced to 3 x 10 5 one/mL.
(18) After domestication, the monoclonal cell strains of 32E2, 37A4, 39A12, 40B10, 4C2 and 6A3 all meet the requirements, which indicates successful domestication.
Example 5: cell shake flask fermentation
(1) Preparation of a subculture medium: 60% CD-CHO +40% Ex-cell 302 was preheated to 37 ℃ in a 37 ℃ water bath.
(2) From CO 2 Taking out the shake flask cells by a constant temperature shaking table, and counting.
(3) The 32E2 and 40B10 cells obtained in example 4 were diluted to 2.5-3.5X 10 5 One cell/mL was inoculated into a 30mL culture medium in a 125mL shake flask. The cell culture flask was left at 37 ℃ and 5% CO 2 Incubate overnight in a constant temperature shaker at 100 rpm/min.
(4) Counting the cell density and the cell activity every 24 hours, measuring glucose, and adding the glucose to 4g/L when the blood sugar is lower than 2 g/L; 1mL of sample was taken daily and the supernatant was used to examine protein expression.
(5) Feeding (about day four): 70g/L CB5 was supplemented, and 10% of the basal medium was added.
(6) Beginning on day 5, CO was added 2 The incubator temperature was adjusted to 32 ℃.
(7) On day nine, 70g/L CB5 was supplemented and 10% of the basal medium was added.
(8) On the fourteenth day, cell supernatants were harvested.
Example 6 construction and acclimatization of recombinant CHO-S cell line stably expressing gB protein
The present inventors also easily constructed a stable cell line expressing recombinant gB protein according to the procedures of examples 1-5, and thus, it is expected that a stable cell line expressing recombinant gB protein can be easily constructed using the method for a commonly-used engineered mammalian cell line, thereby producing the protein on a large scale. Therefore, the present invention is also within the scope of protection.
Example 7: protein purification
The cell culture solution of example 5 (about 100mL per batch) was collected, centrifuged at 4 ℃ for 30min at 8,000g, the supernatant was filtered through a 0.8 μm filter, and 80 μ L of the supernatant was added to 20 μ L of 5 XSDS-sample buffer for SDS-PAGE detection.
Column balancing: balancing 2-3 CV (column volume) with ultrapure water, and discharging ethanol preservation solution; then using BufferA (20 mM NaH) 2 PO 4 (pH 7.4), 500mM NaCl) was equilibrated at 2 to 3CV,4 to 7mL/min.
Loading: if one is used for 5mL pre-packed columns, loading is carried out at 1mL/min (the loading Flow rate is adjusted according to the volume of the pre-packed column, the retention time is 5 min), flow Through (FT) is collected, and 80. Mu.L of sample is added to 20. Mu.L of 5 XSDS-sample buffer for SDS-PAGE detection.
Washing: by 4% of bufferb (20 mM NaH) 2 PO 4 (pH 7.4), 500mM NaCl,20mM imidazole) washing the column at the flow rate of 4mL/min, and washing proteins which are not combined with the column and hybrid proteins with weak combination capacity to be clean until OD280nm base line is stable.
And (3) elution: 50% of buffer B (20 mM NaH) 2 PO 4 (pH 7.4), 500mM NaCl,250mM imidazole) to baseline flush, 2mL/min, collect: 10 mL/tube; after sample mixing (Elutethregh-ET), 80. Mu.L of the sample was added to 20. Mu.L of 5 XSDS-sample buffer for SDS-PAGE detection.
Washing: 100% buffer B (20mM NaH2PO4 (pH 7.4), 500mM NaCl,500mM imidazole), 4mL/min, no collection, 2-3 column volumes washed, until UV baseline wash-out. The ultrapure water is balanced for 2 to 3CV. HisTrap excel columns can be stored with 2-3 CV equilibrium using 20% ethanol storage solution.
And (3) dialysis liquid change: the imidazole eluate containing the target protein was poured into a dialysis bag, dialyzed with 1 XPBS for at least 1,000 times, and 80. Mu.l of the eluate was detected.
And (3) degerming and filtering: in a biosafety cabinet, a 0.22 μm low protein binding needle filter, or Nalgene filter with a 0.22 μm filter sterilized with a large volume of protein solution, was passed through and the filtered protein solution sample was stored in a freezer at-80 ℃.
Protein concentration determination: protein concentration is measured by adopting a BCA method, the protein concentration of the batch is respectively 1.6mg/mL and 2.4mg/mL, and the volume is about 50mL; by calculation (protein yield = protein concentration protein volume/volume of fermentation supernatant taken), the 32E2 and 40B10 strains each had a protein yield of about 0.8-1.2g/L.
Example 8: identification of gB proteins
8.1SDS-PAGE electrophoretic detection
The protein purified in example 6 was subjected to SDS-PAGE, and the gB protein concentration in the sample was 2. Mu.g/well, and the results are shown in FIG. 4: from the figure, it can be calculated that the purified gB protein has an SDS-PAGE purity of 94% and the glycosylated protein has a molecular weight of about 130kD.
8.2Western-blot detection
The purified protein of example 6 was subjected to western-blot assay with a membrane transfer time of 1h, the antibody used was the positive serum of a swine inoculated with pseudorabies attenuated vaccine, the dilution ratio was 1: as can be seen from the results in the figure, the purified gB protein was able to bind to the antibody efficiently.
8.3ELISA detection
(1) Coating: diluting purified gB protein to 0.5 μ g/ml with coating solution (50 mM carbonate buffer, pH 9.5), coating each antigen with 8 wells (4 wells plus PRV positive serum sample, 4 wells plus PRV negative serum as control), adding each antigen with 100 μ l/well, sealing with sealing film, and standing in refrigerator at 4 deg.C overnight;
(2) Washing: after the ELISA plate was removed from the refrigerator, the plate was washed 5 times with PBST;
(3) And (3) sealing: adding 200 μ l of sealing liquid (5% skimmed milk) into each well, sealing with sealing film, and incubating at 37 deg.C for 2 hr;
(4) Serum dilution: diluting the positive serum (14 days after immunization) of PRV (porcine PRV) attenuated vaccine immunized pig by 500 times with blocking solution (such as adding 1 μ l serum into 499 μ l diluent, mixing uniformly), and diluting the negative serum by 500 times;
(5) Washing: the same (2);
(6) Sample adding: adding diluted positive serum and negative serum, and incubating at 37 deg.C for 1h;
(7) Washing: the same as (2);
(8) Adding a secondary antibody: mu.l of a diluted (dilution ratio of 1 to 5000) HRP-labeled rabbit anti-pig IgG secondary antibody was added to each well, and incubated at 37 ℃ for 0.5h;
(9) Washing: the same (2);
(10) Color development: adding 100 mul of TMB color development solution into each hole under the condition of keeping out of the sun, and incubating for 10min at 37 ℃;
(11) And (4) terminating: add 50. Mu.l of stop solution (2M H) to each well 2 SO 4 ) Terminating the reaction;
(12) And (3) detection: measuring OD value of the sample at the wavelength of 450nm, and analyzing data;
(13) The results are shown in the following table: the coated gB protein can be specifically combined with positive serum, and the OD450 mean value is 1.867; neither the coated gB protein specifically bound to negative sera, with an OD450 mean of 0.171. The gB protein can be used as an antigen of an Elisa kit, and a diagnostic kit for detecting the infection and the immunity of the porcine pseudorabies virus can be developed after the appropriate coating concentration and serum dilution ratio are searched.
Example 9 preparation of a gB subunit vaccine
9.1 vaccine preparation
Preparing a water phase: according to the gB protein content in the vaccine, PBS (or normal saline) is used for diluting gB protein to proper concentration, and the gB protein is water phase;
preparing an oil phase: according to the total amount of the prepared vaccine, a proper amount of ISA 201VG adjuvant is measured according to the following weight ratio of an antigen phase to the adjuvant of 1 and the volume ratio of 46;
emulsification: preheating the water phase and oil phase to 33 deg.C, slowly adding the water phase into the oil phase, stirring at 200-500rpm for 20-30min, standing at 20 deg.C for 1h, and standing at 4 deg.C overnight;
subpackaging and storing: subpackaging as required, and storing at 4 deg.C for use after qualified inspection.
9.2 vaccine detection
Physical properties are observed by adopting an eye-watching method to see whether the emulsion is milky white emulsion or not;
sucking a small amount of vaccine by using a clean straw and dripping the vaccine into cold water, observing (except for the 1 st drop), wherein the vaccine is dispersed in a cloud form and is judged to be a water-in-oil-in-water dosage form;
adding 10mL of vaccine into a centrifuge tube, centrifuging for 15min at 3000r/min, and judging the vaccine to be stable if the water separated out from the tube bottom is less than or equal to 0.5 mL;
and (4) performing viscosity detection on the vaccine by using a viscometer, wherein the viscosity detection is required to be within 20-50cp, and the vaccine is judged to be qualified.
9.3gB subunit vaccine for mouse safety experiment
A safety experiment was performed by randomly dividing 16 healthy SPF female mice (purchased from Zhejiang university of traditional Chinese medicine) into 4 groups of 4 mice each, and performing the following procedure.
Single dose one-time immunization group: each group was inoculated with 100. Mu.L (30. Mu.g/mouse) of 4 mice intramuscularly, and observed for 2 weeks continuously.
Single dose secondary immunization group: each group was inoculated with 100. Mu.L (30. Mu.g/mouse) of 4 mice intramuscularly and continuously observed for 2 weeks. After 2 weeks, the cells were inoculated again at the same dose and observed for 2 weeks.
Overdose one-time immunization group: each group was inoculated intramuscularly with 100. Mu.L (300. Mu.g/mouse, 10-fold normal immunization dose) of 4 mice per group, and observed for 2 weeks.
Control group: each group was inoculated intramuscularly with 100. Mu.L of 4 mice (vaccine in PBS) and observed for 2 weeks. During the experiment, the animal's spirit, clinical changes such as feeding, activity, drinking, inflammation change of injection site and excretion condition were observed every day, and abnormal conditions of the animal were recorded.
Through continuous observation, clinical symptoms of mice injected with gB protein are compared, and a single dose, a secondary immunization dose, an overdose immunization group and a control group are normal in diet, free of adverse changes in spirit and normal in excretion, free of inflammation at an injection part, free of dead mice and free of any adverse reaction of inoculated animals. The vaccine protein prepared by the invention has no obvious side effect even if injected at high dose (300 mu g), and is a safe immune protein.
The invention is illustrated by the above examples, but it should be understood that the invention is not limited to the particular examples and embodiments described herein. These specific examples and embodiments are included to assist those skilled in the art in practicing the present invention. Further modifications and improvements will readily occur to those skilled in the art without departing from the spirit and scope of the invention and, accordingly, it is intended that the invention be limited only by the terms of the appended claims, along with the full scope of equivalents to which such terms are entitled.
<110> Zhejiang Hilon Biotechnology Ltd
<120> construction and preparation method of porcine pseudorabies virus gB protein recombinant expression vector
<160>4
<170>PatentIn version 3.3
<210>4
<211>2145
<212>DNA
<213> codon optimized gB protein nucleotide sequence
<400>1
ATGGTGGCTCTGGCCCTGCTGCTGCTGGCTCTGGCTGCTGCTCCACCTTGCGGAGCTGCTGCTGTGACCAGGGCTGCTTCCGCCAGCCCAACACCAGTGCCTGGATCCCCAGGACTGACCCCAAACGACGTGTCCGCTGAGGCCAGCCTGGAGGAGATCGAGGCTTTCACCCCAGGACCATCTGAGGCTCCAGACGGAGAGTACGGCGACCTGGATGCTAGGACAGCCGTGCGGGCTGCTGCTACCGAGAGAGATAGGTTCTACGTGTGCCCCCCTCCATCTGGCTCCACAGTGGTGAGGCTGGAGCCTGAGCAGGCTTGTCCAGAGTACTCCCAGGGCCGGAACTTCACCGAGGGCATCGCCGTGCTGTTTAAGGAGAATATCGCCCCCCACAAGTTCAAGGCTCATATCTACTATAAGAACGTGATCGTGACCACAGTGTGGAGCGGCTCTACATACGCTGCCATCACAAATAGGTTCACCGACCGCGTGCCTGTGCCAGTGCAGGAGATCACCGACGTGATCGATAGGCGGGGCAAGTGCGTGTCCAAGGCTGAGTATGTGAGGAACAATCACAAGGTGACAGCCTTCGACCGGGATGAGAACCCCGTGGAGGTGGACCTGAGACCTAGCCGCCTGAACGCTCTGGGAACCAGGGGATGGCACACCACAAATGATACCCATACAAAGATCGGCGCTGCCGGCTTTTACCATACCGGCACAAGCGTGAATTGTATCGTGGAGGAGGTGGAGGCTAGGTCCGTGTACCCTTATGACTCTTTCGCCCTGTCCACCGGCGATATCGTGTACATGAGCCCCTTCTACGGACTGAGAGAGGGAGCTCACGGAGAGCATATCGGATATGCTCCAGGCCGCTTCCAGCAGGTGGAGCACTACTATCCTATCGACCTGGATTCTAGGCTGCGGGCCTCCGAGAGCGTGACAAGGAACTTCCTGCGGACACCACACTTCACCGTGGCCTGGGACTGGGCTCCCAAGACCAGACGCGTGTGCTCCCTGGCCAAGTGGAGAGAGGCTGAGGAGATGATCAGAGACGAGACACGCGATGGCAGCTTCAGGTTTACCTCTCGGGCTCTGGGAGCCTCCTTCGTGTCCGACGTGACACAGCTGGATCTGCAGAGAGTGCACCTGGGCGACTGCGTGCTGAGGGAGGCTTCTGAGGCCATCGATGCTATCTACCAGAGGCGGTATAACAATACCCATGTGCTGGCCGGCGATAGACCAGAGGTGTACCTGGCTAGGGGAGGATTCGTGGTGGCTTTTCGCCCCCTGATCAGCAATGAGCTGGCCCAGCTGTATGCTAGAGAGCTGGAGCGCCTGGGACTGGCTGGAGTGGTGGGACCAGCTTCTCCTGCTGCTGCTAGAAGGGCTAGGAGGGCTGCTGGACAGGCTGGAACACCTGAGCCACCTGCTGTGAACGGAACCGGACACCTGAGAATCACCACAGGATCCGCCGAGTTCGCTAGGCTGCAGTTTACCTACGACCACATCCAGGCCCATGTGAATGATATGCTGGGAAGGATCGCTGCTGCTTGGTGCGAGCTGCAGAACAAGGACAGGACACTGTGGAGCGAGATGTCTCGGCTGAATCCATCCGCCGTGGCTACCGCTGCCCTGGGACAGAGGGTGTCTGCTCGGATGCTGGGCGATGTGATGGCCATCTCCAGATGCGTGGAGGTGCGCGGAGGCGTGTACGTGCAGAACTCCATGAGGGTGCCTGGAGAGAGGGGAACATGTTATAGCAGACCACTGGTGACATTCGAGCACAACGGAACCGGCGTGATCGAGGGACAGCTGGGCGACGATAATGAGCTGCTGATCTCCCGCGACCTGATCGAGCCTTGTACCGGCAACCATAGACGCTACTTTAAGCTGGGCTCCGGCTACGTGTACTATGAGGATTACAGCTATGTGAGAATGGTCGAGGTGCCCGAGACCATCAGCACACGCGTGACCCTGAATCTGACCCTGCTGGAGGACAGGGAGTTCCTGCCTCTGGAGGTGTACACAAGGGAGGAGCTGGCTGACACCGGACTGCTGGATTATTCTGAGATCCAGAGGCGGAACCAGCTGCACGCCCTGAAGTTTTACGACATCGATAGGGTGGTGAAGGTGGATCATAAT
<210>4
<211>2145
<212>DNA
<213> nucleotide sequence of gB protein before codon optimization
<400>2
ATGGTCGCGCTAGCGCTGCTGCTGCTGGCGCTCGCCGCGGCCCCGCCGTGCGGCGCGGCGGCCGTGACGCGGGCCGCCTCGGCCTCGCCGACGCCCGTCCCGGGCAGCCCCGGCCTCACCCCCAACGACGTCTCCGCGGAGGCGTCCCTCGAGGAGATCGAGGCGTTCACCCCCGGCCCCTCGGAGGCCCCCGACGGCGAGTACGGCGACCTGGACGCGCGCACGGCCGTGCGCGCGGCCGCGACCGAGCGGGACCGCTTCTACGTCTGCCCGCCGCCGTCCGGCTCCACGGTGGTGCGCCTGGAGCCCGAGCAGGCCTGCCCCGAGTACTCGCAGGGGCGCAACTTCACGGAGGGGATCGCCGTGCTCTTCAAGGAGAACATCGCCCCGCACAAGTTCAAGGCCCACATCTACTACAAGAACGTCATCGTCACGACCGTGTGGTCCGGGAGCACGTACGCGGCCATCACGAACCGCTTCACGGACCGCGTGCCCGTCCCCGTGCAGGAGATCACGGACGTGATCGACCGCCGCGGCAAGTGCGTCTCCAAGGCCGAGTACGTGCGCAACAACCACAAGGTGACCGCCTTCGACCGCGACGAGAACCCCGTCGAGGTGGACCTGCGCCCCTCGCGCCTGAACGCGCTCGGCACCCGCGGCTGGCACACCACCAACGACACCCACACCAAGATCGGCGCCGCGGGCTTCTACCACACGGGCACCTCCGTCAACTGCATCGTCGAGGAGGTGGAGGCGCGCTCCGTGTACCCCTACGACTCCTTCGCCCTGTCCACGGGGGACATTGTGTACATGTCCCCCTTCTACGGCCTGCGCGAGGGGGCCCACGGGGAGCACATCGGCTACGCGCCCGGGCGCTTCCAGCAGGTGGAGCACTACTACCCCATCGACCTGGACTCGCGCCTCCGCGCCTCCGAGAGCGTGACGCGCAACTTTCTGCGCACGCCGCACTTCACGGTGGCCTGGGACTGGGCCCCCAAGACGCGGCGCGTGTGCAGCCTGGCCAAGTGGCGCGAGGCCGAGGAGATGATCCGCGACGAGACGCGCGACGGGTCCTTCCGCTTCACGTCGCGGGCCCTGGGCGCCTCCTTCGTCAGCGACGTCACGCAGCTGGACCTGCAGCGCGTGCACCTGGGCGACTGCGTCCTCCGCGAGGCCTCGGAGGCCATCGACGCCATCTACCAGCGGCGCTACAACAACACGCACGTGCTGGCCGGCGACAGGCCCGAGGTGTACCTCGCCCGCGGGGGCTTCGTGGTGGCCTTCCGCCCGCTGATCTCGAACGAGCTGGCGCAGCTGTACGCGCGCGAGCTCGAGCGCCTCGGCCTCGCCGGCGTCGTGGGCCCCGCGTCCCCCGCGGCGGCCCGGCGGGCCCGGCGCGCCGCCGGACAGGCGGGGACGCCCGAGCCGCCGGCCGTCAACGGCACGGGGCACCTGCGCATCACCACGGGCTCGGCGGAGTTTGCGCGCCTGCAGTTCACCTACGACCACATCCAGGCGCACGTGAACGACATGCTGGGCCGCATCGCGGCCGCCTGGTGCGAGCTGCAGAACAAGGACCGCACCCTGTGGAGCGAGATGTCGCGCCTGAACCCCAGCGCCGTGGCCACGGCCGCGCTCGGCCAGCGCGTCTCGGCGCGCATGCTCGGCGACGTGATGGCCATCTCGCGGTGCGTGGAGGTGCGCGGCGGCGTGTACGTGCAGAACTCCATGCGCGTGCCCGGCGAGCGCGGCACGTGCTACAGCCGCCCGCTGGTCACCTTCGAGCACAACGGCACGGGCGTGATCGAGGGCCAGCTCGGCGACGACAACGAGCTCCTCATCTCGCGCGACCTCATCGAGCCCTGCACCGGCAACCACCGGCGCTACTTTAAGCTGGGGAGCGGGTACGTGTACTACGAGGACTACAGCTACGTGCGCATGGTGGAGGTGCCCGAGACGATCAGCACGCGGGTGACCCTGAACCTGACGCTGCTGGAGGACCGCGAGTTCCTGCCCCTCGAGGTGTACACGCGCGAGGAGCTCGCCGACACGGGCCTCCTGGACTACAGCGAGATCCAGCGCCGCAACCAGCTGCACGCGCTCAAGTTCTACGACATCGACCGCGTGGTCAAGGTGGACCACAAC
<210>4
<211>715
<212>PRT
<213> amino acid sequence of gB protein
<400>3
MVALALLLLALAAAPPCGAAAVTRAASASPTPVPGSPGLTPNDVSAEASLEEIEAFTPGPSEAPDGEYGDLDARTAVRAAATERDRFYVCPPPSGSTVVRLEPEQACPEYSQGRNFTEGIAVLFKENIAPHKFKAHIYYKNVIVTTVWSGSTYAAITNRFTDRVPVPVQEITDVIDRRGKCVSKAEYVRNNHKVTAFDRDENPVEVDLRPSRLNALGTRGWHTTNDTHTKIGAAGFYHTGTSVNCIVEEVEARSVYPYDSFALSTGDIVYMSPFYGLREGAHGEHIGYAPGRFQQVEHYYPIDLDSRLRASESVTRNFLRTPHFTVAWDWAPKTRRVCSLAKWREAEEMIRDETRDGSFRFTSRALGASFVSDVTQLDLQRVHLGDCVLREASEAIDAIYQRRYNNTHVLAGDRPEVYLARGGFVVAFRPLISNELAQLYARELERLGLAGVVGPASPAAARRARRAAGQAGTPEPPAVNGTGHLRITTGSAEFARLQFTYDHIQAHVNDMLGRIAAAWCELQNKDRTLWSEMSRLNPSAVATAALGQRVSARMLGDVMAISRCVEVRGGVYVQNSMRVPGERGTCYSRPLVTFEHNGTGVIEGQLGDDNELLISRDLIEPCTGNHRRYFKLGSGYVYYEDYSYVRMVEVPETISTRVTLNLTLLEDREFLPLEVYTREELADTGLLDYSEIQRRNQLHALKFYDIDRVVKVDHN
Sequence listing
<110> Zhejiang Hailong Biotechnology Ltd
<120> gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof
<160> 4
<170> PatentIn version 3.3
<210> 4
<211> 2145
<212> DNA
<213> codon-optimized nucleotide sequence (DNA) of gB protein
<400> 1
ATGGTGGCTCTGGCCCTGCTGCTGCTGGCTCTGGCTGCTGCTCCACCTTGCGGAGCTGCTGCTGTGACCAGGGCTGCTTCCGCCAGCCCAACACCAGTGCCTGGATCCCCAGGACTGACCCCAAACGACGTGTCCGCTGAGGCCAGCCTGGAGGAGATCGAGGCTTTCACCCCAGGACCATCTGAGGCTCCAGACGGAGAGTACGGCGACCTGGATGCTAGGACAGCCGTGCGGGCTGCTGCTACCGAGAGAGATAGGTTCTACGTGTGCCCCCCTCCATCTGGCTCCACAGTGGTGAGGCTGGAGCCTGAGCAGGCTTGTCCAGAGTACTCCCAGGGCCGGAACTTCACCGAGGGCATCGCCGTGCTGTTTAAGGAGAATATCGCCCCCCACAAGTTCAAGGCTCATATCTACTATAAGAACGTGATCGTGACCACAGTGTGGAGCGGCTCTACATACGCTGCCATCACAAATAGGTTCACCGACCGCGTGCCTGTGCCAGTGCAGGAGATCACCGACGTGATCGATAGGCGGGGCAAGTGCGTGTCCAAGGCTGAGTATGTGAGGAACAATCACAAGGTGACAGCCTTCGACCGGGATGAGAACCCCGTGGAGGTGGACCTGAGACCTAGCCGCCTGAACGCTCTGGGAACCAGGGGATGGCACACCACAAATGATACCCATACAAAGATCGGCGCTGCCGGCTTTTACCATACCGGCACAAGCGTGAATTGTATCGTGGAGGAGGTGGAGGCTAGGTCCGTGTACCCTTATGACTCTTTCGCCCTGTCCACCGGCGATATCGTGTACATGAGCCCCTTCTACGGACTGAGAGAGGGAGCTCACGGAGAGCATATCGGATATGCTCCAGGCCGCTTCCAGCAGGTGGAGCACTACTATCCTATCGACCTGGATTCTAGGCTGCGGGCCTCCGAGAGCGTGACAAGGAACTTCCTGCGGACACCACACTTCACCGTGGCCTGGGACTGGGCTCCCAAGACCAGACGCGTGTGCTCCCTGGCCAAGTGGAGAGAGGCTGAGGAGATGATCAGAGACGAGACACGCGATGGCAGCTTCAGGTTTACCTCTCGGGCTCTGGGAGCCTCCTTCGTGTCCGACGTGACACAGCTGGATCTGCAGAGAGTGCACCTGGGCGACTGCGTGCTGAGGGAGGCTTCTGAGGCCATCGATGCTATCTACCAGAGGCGGTATAACAATACCCATGTGCTGGCCGGCGATAGACCAGAGGTGTACCTGGCTAGGGGAGGATTCGTGGTGGCTTTTCGCCCCCTGATCAGCAATGAGCTGGCCCAGCTGTATGCTAGAGAGCTGGAGCGCCTGGGACTGGCTGGAGTGGTGGGACCAGCTTCTCCTGCTGCTGCTAGAAGGGCTAGGAGGGCTGCTGGACAGGCTGGAACACCTGAGCCACCTGCTGTGAACGGAACCGGACACCTGAGAATCACCACAGGATCCGCCGAGTTCGCTAGGCTGCAGTTTACCTACGACCACATCCAGGCCCATGTGAATGATATGCTGGGAAGGATCGCTGCTGCTTGGTGCGAGCTGCAGAACAAGGACAGGACACTGTGGAGCGAGATGTCTCGGCTGAATCCATCCGCCGTGGCTACCGCTGCCCTGGGACAGAGGGTGTCTGCTCGGATGCTGGGCGATGTGATGGCCATCTCCAGATGCGTGGAGGTGCGCGGAGGCGTGTACGTGCAGAACTCCATGAGGGTGCCTGGAGAGAGGGGAACATGTTATAGCAGACCACTGGTGACATTCGAGCACAACGGAACCGGCGTGATCGAGGGACAGCTGGGCGACGATAATGAGCTGCTGATCTCCCGCGACCTGATCGAGCCTTGTACCGGCAACCATAGACGCTACTTTAAGCTGGGCTCCGGCTACGTGTACTATGAGGATTACAGCTATGTGAGAATGGTCGAGGTGCCCGAGACCATCAGCACACGCGTGACCCTGAATCTGACCCTGCTGGAGGACAGGGAGTTCCTGCCTCTGGAGGTGTACACAAGGGAGGAGCTGGCTGACACCGGACTGCTGGATTATTCTGAGATCCAGAGGCGGAACCAGCTGCACGCCCTGAAGTTTTACGACATCGATAGGGTGGTGAAGGTGGATCATAAT
<210> 4
<211> 2145
<212> DNA
<213> nucleotide sequence (DNA) of gB protein before codon optimization
<400> 2
ATGGTCGCGCTAGCGCTGCTGCTGCTGGCGCTCGCCGCGGCCCCGCCGTGCGGCGCGGCGGCCGTGACGCGGGCCGCCTCGGCCTCGCCGACGCCCGTCCCGGGCAGCCCCGGCCTCACCCCCAACGACGTCTCCGCGGAGGCGTCCCTCGAGGAGATCGAGGCGTTCACCCCCGGCCCCTCGGAGGCCCCCGACGGCGAGTACGGCGACCTGGACGCGCGCACGGCCGTGCGCGCGGCCGCGACCGAGCGGGACCGCTTCTACGTCTGCCCGCCGCCGTCCGGCTCCACGGTGGTGCGCCTGGAGCCCGAGCAGGCCTGCCCCGAGTACTCGCAGGGGCGCAACTTCACGGAGGGGATCGCCGTGCTCTTCAAGGAGAACATCGCCCCGCACAAGTTCAAGGCCCACATCTACTACAAGAACGTCATCGTCACGACCGTGTGGTCCGGGAGCACGTACGCGGCCATCACGAACCGCTTCACGGACCGCGTGCCCGTCCCCGTGCAGGAGATCACGGACGTGATCGACCGCCGCGGCAAGTGCGTCTCCAAGGCCGAGTACGTGCGCAACAACCACAAGGTGACCGCCTTCGACCGCGACGAGAACCCCGTCGAGGTGGACCTGCGCCCCTCGCGCCTGAACGCGCTCGGCACCCGCGGCTGGCACACCACCAACGACACCCACACCAAGATCGGCGCCGCGGGCTTCTACCACACGGGCACCTCCGTCAACTGCATCGTCGAGGAGGTGGAGGCGCGCTCCGTGTACCCCTACGACTCCTTCGCCCTGTCCACGGGGGACATTGTGTACATGTCCCCCTTCTACGGCCTGCGCGAGGGGGCCCACGGGGAGCACATCGGCTACGCGCCCGGGCGCTTCCAGCAGGTGGAGCACTACTACCCCATCGACCTGGACTCGCGCCTCCGCGCCTCCGAGAGCGTGACGCGCAACTTTCTGCGCACGCCGCACTTCACGGTGGCCTGGGACTGGGCCCCCAAGACGCGGCGCGTGTGCAGCCTGGCCAAGTGGCGCGAGGCCGAGGAGATGATCCGCGACGAGACGCGCGACGGGTCCTTCCGCTTCACGTCGCGGGCCCTGGGCGCCTCCTTCGTCAGCGACGTCACGCAGCTGGACCTGCAGCGCGTGCACCTGGGCGACTGCGTCCTCCGCGAGGCCTCGGAGGCCATCGACGCCATCTACCAGCGGCGCTACAACAACACGCACGTGCTGGCCGGCGACAGGCCCGAGGTGTACCTCGCCCGCGGGGGCTTCGTGGTGGCCTTCCGCCCGCTGATCTCGAACGAGCTGGCGCAGCTGTACGCGCGCGAGCTCGAGCGCCTCGGCCTCGCCGGCGTCGTGGGCCCCGCGTCCCCCGCGGCGGCCCGGCGGGCCCGGCGCGCCGCCGGACAGGCGGGGACGCCCGAGCCGCCGGCCGTCAACGGCACGGGGCACCTGCGCATCACCACGGGCTCGGCGGAGTTTGCGCGCCTGCAGTTCACCTACGACCACATCCAGGCGCACGTGAACGACATGCTGGGCCGCATCGCGGCCGCCTGGTGCGAGCTGCAGAACAAGGACCGCACCCTGTGGAGCGAGATGTCGCGCCTGAACCCCAGCGCCGTGGCCACGGCCGCGCTCGGCCAGCGCGTCTCGGCGCGCATGCTCGGCGACGTGATGGCCATCTCGCGGTGCGTGGAGGTGCGCGGCGGCGTGTACGTGCAGAACTCCATGCGCGTGCCCGGCGAGCGCGGCACGTGCTACAGCCGCCCGCTGGTCACCTTCGAGCACAACGGCACGGGCGTGATCGAGGGCCAGCTCGGCGACGACAACGAGCTCCTCATCTCGCGCGACCTCATCGAGCCCTGCACCGGCAACCACCGGCGCTACTTTAAGCTGGGGAGCGGGTACGTGTACTACGAGGACTACAGCTACGTGCGCATGGTGGAGGTGCCCGAGACGATCAGCACGCGGGTGACCCTGAACCTGACGCTGCTGGAGGACCGCGAGTTCCTGCCCCTCGAGGTGTACACGCGCGAGGAGCTCGCCGACACGGGCCTCCTGGACTACAGCGAGATCCAGCGCCGCAACCAGCTGCACGCGCTCAAGTTCTACGACATCGACCGCGTGGTCAAGGTGGACCACAAC
<210> 4
<211> 715
<212> PRT
<213> amino acid sequence (PRT) of gB protein
<400> 3
MVALALLLLALAAAPPCGAAAVTRAASASPTPVPGSPGLTPNDVSAEASLEEIEAFTPGPSEAPDGEYGDLDARTAVRAAATERDRFYVCPPPSGSTVVRLEPEQACPEYSQGRNFTEGIAVLFKENIAPHKFKAHIYYKNVIVTTVWSGSTYAAITNRFTDRVPVPVQEITDVIDRRGKCVSKAEYVRNNHKVTAFDRDENPVEVDLRPSRLNALGTRGWHTTNDTHTKIGAAGFYHTGTSVNCIVEEVEARSVYPYDSFALSTGDIVYMSPFYGLREGAHGEHIGYAPGRFQQVEHYYPIDLDSRLRASESVTRNFLRTPHFTVAWDWAPKTRRVCSLAKWREAEEMIRDETRDGSFRFTSRALGASFVSDVTQLDLQRVHLGDCVLREASEAIDAIYQRRYNNTHVLAGDRPEVYLARGGFVVAFRPLISNELAQLYARELERLGLAGVVGPASPAAARRARRAAGQAGTPEPPAVNGTGHLRITTGSAEFARLQFTYDHIQAHVNDMLGRIAAAWCELQNKDRTLWSEMSRLNPSAVATAALGQRVSARMLGDVMAISRCVEVRGGVYVQNSMRVPGERGTCYSRPLVTFEHNGTGVIEGQLGDDNELLISRDLIEPCTGNHRRYFKLGSGYVYYEDYSYVRMVEVPETISTRVTLNLTLLEDREFLPLEVYTREELADTGLLDYSEIQRRNQLHALKFYDIDRVVKVDHN
Claims (8)
1. The gB subunit recombinant protein of the porcine pseudorabies virus is characterized in that the gB subunit recombinant protein is an extracellular region of the gB protein, the amino acid sequence of the gB subunit recombinant protein is shown in SEQ ID No.3, the gene sequence coded by the gB subunit recombinant protein is shown in SEQ ID No.2, the gene sequence coded by the gB subunit recombinant protein can efficiently secrete and express an optimized gB gene sequence of the gB subunit protein in CHO cells, and the optimized gB gene sequence is shown in SEQ ID No. 1.
2. The gB subunit recombinant protein according to claim 1, wherein the gB subunit recombinant protein is linked to a detection or purification tag at the amino terminus or the carboxy terminus of the amino acid sequence shown in SEQ ID No.3, wherein the tag is selected from one of ploy-Arg, ploy-His, FLAG, c-myc, and HA.
3. A method for preparing a recombinant protein of gB subunit of porcine pseudorabies virus according to any of claims 1 to 2, comprising the steps of:
1) Cloning the optimized gB gene sequence shown as SEQ ID NO.1 into a eukaryotic expression vector to obtain a recombinant plasmid containing a gB subunit protein coding gene of the pseudorabies virus;
2) Then the recombinant plasmid containing the gB subunit protein coding gene of the pseudorabies virus is transfected into an expression cell;
3) Culturing, screening and domesticating the expression cells in the step 2) to obtain a highly expressed cell strain;
4) Fermenting and culturing the cell strain in the step 3), and purifying to obtain gB subunit protein of the pseudorabies virus, wherein the amino acid sequence of the gB subunit protein is shown as SEQ ID NO. 3.
4. The method of claim 3, wherein in step 1), the eukaryotic expression vector is pEE12.4 or pcDNA3.1.
5. The method according to claim 3, wherein in step 2), the expression cells are mammalian cells.
6. The method of claim 5, wherein the mammalian cell is a CHO cell or a 293T cell.
7. The method of claim 6, wherein the CHO cells comprise DG44, DXB11, CHO-K1, CHO-S cell lines.
8. Use of a recombinant protein of the gB subunit of porcine pseudorabies virus according to any one of claims 1-2 for the preparation of a vaccine for the diagnosis, prevention and treatment of porcine pseudorabies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577700.XA CN112142827B (en) | 2019-06-28 | 2019-06-28 | gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577700.XA CN112142827B (en) | 2019-06-28 | 2019-06-28 | gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112142827A CN112142827A (en) | 2020-12-29 |
| CN112142827B true CN112142827B (en) | 2023-02-03 |
Family
ID=73869563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910577700.XA Active CN112142827B (en) | 2019-06-28 | 2019-06-28 | gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112142827B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113173976B (en) * | 2021-06-03 | 2022-07-12 | 北京市农林科学院 | Canine influenza virus H3 subtype HA protein, and preparation method and application thereof |
| CN114908056B (en) * | 2022-05-18 | 2024-04-16 | 华中农业大学 | Recombinant CHO cell line expressing pig PRV gDFc or gBFc fusion protein and construction method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693827A (en) * | 2015-06-29 | 2016-06-22 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus subunit vaccine and preparation method and application thereof |
| CN106267182A (en) * | 2015-06-29 | 2017-01-04 | 普莱柯生物工程股份有限公司 | The preparation method of a kind of porcine pseudorabies virus subunit vaccine and vaccine combination and application |
| CN107485712A (en) * | 2017-08-09 | 2017-12-19 | 扬州优邦生物药品有限公司 | A kind of PRV subunit vaccine and its preparation method and application |
| CN109206491A (en) * | 2017-07-07 | 2019-01-15 | 浙江海隆生物科技有限公司 | Preparation method of porcine pseudorabies virus gD protein, porcine pseudorabies virus subunit vaccine and application |
-
2019
- 2019-06-28 CN CN201910577700.XA patent/CN112142827B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693827A (en) * | 2015-06-29 | 2016-06-22 | 普莱柯生物工程股份有限公司 | Porcine pseudorabies virus subunit vaccine and preparation method and application thereof |
| CN106267182A (en) * | 2015-06-29 | 2017-01-04 | 普莱柯生物工程股份有限公司 | The preparation method of a kind of porcine pseudorabies virus subunit vaccine and vaccine combination and application |
| CN109206491A (en) * | 2017-07-07 | 2019-01-15 | 浙江海隆生物科技有限公司 | Preparation method of porcine pseudorabies virus gD protein, porcine pseudorabies virus subunit vaccine and application |
| CN107485712A (en) * | 2017-08-09 | 2017-12-19 | 扬州优邦生物药品有限公司 | A kind of PRV subunit vaccine and its preparation method and application |
Non-Patent Citations (4)
| Title |
|---|
| María Soledad Serena等.Production of pseudorabies virus recombinant glycoprotein B and its use in an agar gel immunodiffusion (AGID) test for detection of antibodies with sensitivity and specificity equal to the virus neutralization assay.《Journal of Virological Methods》.2016, * |
| Production of Aujeszky"s disease (pseudorabies) virus envelope glycoproteins gB and gC as recombinant polyhedra in baculovirus-infected silkworm larvae;Bo Yeon Kim等;《Journal of Asia-Pacific Entomology》;20121231;第114-120页 * |
| Production of pseudorabies virus recombinant glycoprotein B and its use in an agar gel immunodiffusion (AGID) test for detection of antibodies with sensitivity and specificity equal to the virus neutralization assay;María Soledad Serena等;《Journal of Virological Methods》;20160119;第9-12页 * |
| 伪狂犬病病毒gB基因的原核表达及间接ELISA方法的建立;王雨等;《动物医学进展》;20151231;第19-23页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112142827A (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111471089B (en) | Recombinant African swine fever virus CD2V subunit protein and preparation method and application thereof | |
| CN111393531B (en) | Subunit fusion protein CD2V-Fc and preparation method and application thereof | |
| US10925959B2 (en) | Porcine epidemic diarrhea virus S protein and subunit vaccine thereof as well as method for preparing subunit vaccine and application thereof | |
| CN111234036B (en) | African swine fever virus p72 fusion protein and preparation method and application thereof | |
| CN108159409A (en) | A kind of 3 type Cap protein vaccine of pig circular ring virus and its preparation method and application | |
| CN110041411B (en) | Stable atypical swine fever virus subunit protein, vaccine, preparation method and application thereof | |
| CN110317278B (en) | Fusion protein of SVV and FMDV, encoding gene, expression vector, cell line, engineering bacterium, vaccine and application thereof | |
| CN112142851B (en) | Subunit fusion protein tG on rabies virus surface and preparation method and application thereof | |
| CN116813720A (en) | Preparation method of porcine pseudorabies virus gD protein, porcine pseudorabies virus subunit vaccine and application | |
| CN110981968B (en) | Fusion protein containing rabies virus G protein, preparation method, application and vaccine thereof | |
| CN107973841B (en) | Preparation method and application of recombinant bovine viral diarrhea virus E2 protein expressed by CHO (Chinese hamster ovary) cell and subunit vaccine | |
| CN112142827B (en) | gB subunit recombinant protein of porcine pseudorabies virus, and preparation method and application thereof | |
| CN111607001A (en) | Recombinant soluble African swine fever virus p72 subunit fusion protein and preparation method and application thereof | |
| CN114163505B (en) | Swine fever and porcine pseudorabies virus bigeminal subunit vaccine and preparation method thereof | |
| CN111875676A (en) | P49 mutant protein of African swine fever virus immunogen, recombinant vector, Escherichia coli genetic engineering bacteria, preparation method and application | |
| CN115025212A (en) | mRNA vaccine for preventing porcine reproductive and respiratory syndrome and preparation method thereof | |
| WO2018188639A1 (en) | Porcine epidemic diarrhea virus s protein, subunit vaccine thereof, and preparation method for and application of the subunit vaccine | |
| CN112430273A (en) | Subunit fusion protein mG on rabies virus surface as well as preparation method and application thereof | |
| CN111378017B (en) | Subunit F protein of peste des petits ruminants virus and preparation method and application thereof | |
| CN112341525A (en) | Recombinant African swine fever virus pE120R subunit soluble protein and preparation method and application thereof | |
| CN111607000A (en) | Recombinant soluble African swine fever virus p30 subunit fusion protein and preparation method and application thereof | |
| CN111378016B (en) | Subunit H protein of peste des petits ruminants virus, preparation method and application thereof | |
| CN116655751A (en) | Preparation method and application of recombinant swine fever E2 protein and subunit vaccine thereof | |
| CN111304173B (en) | Recombinant CHO cell strain for efficiently expressing classical swine fever E2-IL1 fusion protein and construction method and application thereof | |
| CN109265522B (en) | Sensitized polystyrene nano-microsphere for detecting canine distemper virus hemagglutinin H antibody and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Applicant after: NOVO BIOTECH Corp. Address before: 312000 5th floor, building 2, science and innovation center, 398 mahuan Road, Binhai New Town, Shaoxing City, Zhejiang Province Applicant before: NOVO BIOTECH Corp. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee after: Zhejiang Hailong Biotechnology Co.,Ltd. Country or region after: China Address before: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee before: NOVO BIOTECH Corp. Country or region before: China |
|
| CP03 | Change of name, title or address |